Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes | Entera Bio Ltd.
undefined
Mar 8, 2020
en.globes.co.il
Opko jumps on Covid-19 diagnostic lab announcement
#Customers #Investment
Oct 23, 2019
en.globes.co.il
Opko Health seeks $100m in NYSE public offering
#Investment
Feb 5, 2019
en.globes.co.il
Opko to activate shelf prospectus to raise $200m
#Investment
Apr 29, 2018
www.calcalistech.com
Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
#Public Trading
Apr 10, 2018
www.globes.co.il
Opko Health to delist from TASE
#Public Trading
Apr 16, 2014
www.globes.co.il
Opko turns Prolor into Israeli R&D, investment arm
#Acquisition
Dec 21, 2011
www.globes.co.il
OPKO Health buys FineTech Pharmaceutical for $27.5m
#Acquisition
About
OPKO Health Inc is a multinational corporation that researches, develops, and produces a variety of pharmaceutical technologies. The company pursues diagnostics, genetic testing, cancer treatment, fertility, growth hormone deficiency, and other areas of pharmaceutical research.
OPKO Israel encompasses two main entities: OPKO Biologics and FineTech Pharmaceutical. OPKO Biologics, previously known as Prolor Biotech, is a clinical-stage company that concentrates on creating long-acting versions of therapeutic proteins and peptide drugs. They employ advanced technologies such as CTP, reversible PEGylation, and native stabilizer proteins. On the other hand, FineTech is involved in the development of high-value Active Pharmaceutical Ingredients (APIs) and devises methods to bypass patents, facilitating faster commercial progress for its pharmaceutical clients.
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes | Entera Bio Ltd.
undefined
Mar 8, 2020
en.globes.co.il
Opko jumps on Covid-19 diagnostic lab announcement
#Customers #Investment
Oct 23, 2019
en.globes.co.il
Opko Health seeks $100m in NYSE public offering
#Investment
Feb 5, 2019
en.globes.co.il
Opko to activate shelf prospectus to raise $200m
#Investment
Apr 29, 2018
www.calcalistech.com
Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
#Public Trading
Apr 10, 2018
www.globes.co.il
Opko Health to delist from TASE
#Public Trading
Apr 16, 2014
www.globes.co.il
Opko turns Prolor into Israeli R&D, investment arm
#Acquisition
Dec 21, 2011
www.globes.co.il
OPKO Health buys FineTech Pharmaceutical for $27.5m